Quantum BioPharma Announces $750 Private Placement to Restore Founder Voting Control

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The offering, which received shareholder approval on September 26, 2025, is expected to be fully subscribed by entities controlled by company founders Zeeshan Saeed and Anthony Durkacz.

The transaction carries significant implications for corporate governance as the voting rights attached to the Class A shares will increase to 75.27% upon completion, effectively restoring founder control to nearly its original level when the company went public in 2018. This concentration of voting power represents a substantial shift in shareholder influence and corporate decision-making authority at the biopharmaceutical firm.

Proceeds from the private placement will be allocated to general working capital, supporting the company's ongoing operations and development pipeline. Quantum BioPharma focuses on building a portfolio of innovative treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in various stages of development.

Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing its lead compound Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning Lucid-MS as a potential breakthrough treatment for this debilitating neurological condition. Additional information about the company's development programs is available at https://ibn.fm/QNTM.

Quantum BioPharma also maintains strategic interests in consumer health products through its ownership stake in Unbuzzd Wellness Inc. The company retains 20.11% ownership of Unbuzzd Wellness as of March 31, 2025, along with royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty decreases to 3% in perpetuity. Importantly, Quantum BioPharma retains full rights to develop similar products specifically for pharmaceutical and medical applications.

The private placement announcement was disseminated through InvestorWire, a specialized communications platform that provides wire-grade press release syndication services. More details about the distribution platform can be found at https://www.InvestorWire.com. The full press release containing additional details about the financing is accessible at https://ibn.fm/aicDo.

This financing move comes as the company continues to advance its therapeutic pipeline while maintaining its strategic investment portfolio through subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. The restoration of founder voting control through this relatively small capital raise highlights the ongoing balance between funding operations and maintaining corporate control in the competitive biopharmaceutical sector.